Evidence map›Paper›PMID 28535793›Full record

ArticleMalaria journal2017

Intermittent preventive treatment for malaria among children in a refugee camp in Northern Uganda: lessons learned.

Matthew E Coldiron, Estrella Lasry, Malika Bouhenia, Debashish Das, Peter Okui, Dan Nyehangane, Juliet Mwanga, Celine Langendorf, Greg Elder, Léon Salumu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Matthew E ColdironEpicentre, 8 Rue Saint-Sabin, Paris, France. matthew.coldiron@epicentre.msf.org.ORCID 0000-0002-3345-5971
Estrella LasryMédecins Sans Frontières, New York, USA.
Malika BouheniaEpicentre, 8 Rue Saint-Sabin, Paris, France.
Debashish DasEpicentre, 8 Rue Saint-Sabin, Paris, France.
Peter OkuiNational Malaria Control Programme, Ministry of Health, Kampala, Uganda.
Dan NyehanganeEpicentre, Mbarara, Uganda.
Juliet MwangaEpicentre, Mbarara, Uganda.
Celine LangendorfEpicentre, 8 Rue Saint-Sabin, Paris, France.
Greg ElderEpicentre, 8 Rue Saint-Sabin, Paris, France.
Léon SalumuEpicentre, 8 Rue Saint-Sabin, Paris, France.
Rebecca F GraisEpicentre, 8 Rue Saint-Sabin, Paris, France.
Epicentre Uganda · UGEpicentre (South Africa) · ZAMédecins Sans Frontières · USMinistry of Health · UG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Northern Uganda hosts a large population of refugees from South Sudan, and malaria is one of the major health problems in the area. In 2015, intermittent preventive treatment for malaria (IPTc) was implemented in two refugee camps among children aged 6 months to 14 years. Three distributions of dihydroartemisinin-piperaquine (DP) were conducted at 8-week intervals. The first dose was directly administered at IPTc distribution sites and the second and third doses were given to caregivers to administer at home. A multi-faceted evaluation was implemented, including coverage surveys, malaria prevalence surveys, reinforced surveillance, and pharmacovigilance. Programme coverage exceeded 90% during all three distributions with a total of 40,611 participants. Compared to same period during the previous year (only available data), the incidence of malaria in the target populations was reduced (IRR 0.73, 95% CI 0.69-0.77 among children under 5 years old; IRR 0.70, 95% CI 0.67-0.72 among children aged 5-14 years). Among those not targeted for intervention, the incidence between the 2 years increased (IRR 1.49, 95% CI 1.42-1.56). Cross-sectional surveys showed a prevalence of parasitaemia (microscopy or PCR) of 12.9-16.4% (95% CI 12.6-19.3) during the intervention, with the highest prevalence among children aged 5-14 years, but with a large increase 8 weeks after the final distribution. A total of 57 adverse events were reported during the intervention period, including one severe adverse event (death from varicella). Adverse events were of mild to moderate severity, and were mainly dermatologic and gastrointestinal. This is the first documentation of an IPTc programme in a refugee camp. The positive impact of DP on the incidence of malaria, together with its favourable safety profile, should lead to further use of IPTc in similar settings. Expanding coverage groups and decreasing intervals between distributions might provide more benefit, but would need to be balanced with the operational implications of a broader, more frequent distribution schedule.

Indexed as

Refugee CampsAdolescentAntimalarialsArtemisininsChildChild, PreschoolCross-Sectional StudiesDrug CombinationsFemaleHumansIncidenceInfantMalariaMaleParasitemiaPiperazinesAntimalarialsArtemisininsartenimolDrug CombinationspiperaquinePiperazinesQuinolinesAnti-malarialsArtemisininMalariaQuinolinesRefugeeSouth SudanUganda

Identifiers

PMID28535793
PMCPMC5442684
OpenAlexW2620469587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.